Immunotherapies in development for the treatment of chronic lymphocytic leukemia
| Trial | Agents investigated | Agent description | Primary outcome for assessment |
| ZUMA-8 (NCT03624036) | brexucabtagene autoleucel for R/R CLL | CAR T cell | Rate of dose-limiting toxicity, ORR |
| TRANSCEND-CLL-004 (NCT03331198) | JCAR017 (lisocabtagene maraleucel) vs JCAR017+ibrutinib for R/R CLL | CAR T cell and BTKi | Recommended dose, rate of AEs, rate of laboratory abnormalities, CR rate |
| NCT00774345 | Lenalidomide vs placebo for maintenance of CLL | IMiD | OS, PFS |
| GAIA (NCT02950051) | Rituximab-FC+venetoclax vs obinutuzumab+venetoclax vs obinutuzumab+venetoclax+ibrutinib for first-line CLL | mAb | MRD negativity rate, PFS |
| GENUINE (NCT02301156) | Ublituximab+ibrutinib vs ibrutinib | mAb | ORR, PFS |
| UNITY-CLL (NCT02612311) | Ublituximab+TGR-1202 vs obinutuzumab+chlorambucil vs ublituximab vs TGR-1202 for first-line and R/R CLL | mAb | PFS |
AEs, adverse events; BTKi, Bruton’s tyrosine kinase inhibitor; CLL, chronic lymphocytic leukemia; CR, complete remission; FC, fludarabine, cyclophosphamide; IMiD, immunomodulatory drug; mAb, monoclonal antibody; MRD, minimal residual disease; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; R/R, relapsed or refractory.